Last reviewed · How we verify
Cyclophosphamide injections
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Breast cancer, Ovarian cancer.
At a glance
| Generic name | Cyclophosphamide injections |
|---|---|
| Sponsor | Astellas Pharma China, Inc. |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is a nitrogen mustard derivative that forms reactive intermediates which bind to DNA and create cross-links between DNA strands. This prevents DNA replication and transcription, leading to cell death. It is particularly effective against rapidly dividing cells, including cancer cells and activated lymphocytes, making it useful in both oncology and immunosuppressive applications.
Approved indications
- Lymphomas (Hodgkin and non-Hodgkin)
- Breast cancer
- Ovarian cancer
- Leukemias
- Multiple myeloma
- Severe rheumatoid arthritis (immunosuppressive use)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Alopecia
- Hemorrhagic cystitis
- Infertility
- Secondary malignancies
- Immunosuppression/infections
Key clinical trials
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)
- Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (PHASE1)
- Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide injections CI brief — competitive landscape report
- Cyclophosphamide injections updates RSS · CI watch RSS
- Astellas Pharma China, Inc. portfolio CI